PetMed Express Inc (PETS)

20.29
0.04 0.22
NASDAQ : Health Care
Prev Close 20.24
Open 20.20
Day Low/High 19.98 / 20.39
52 Wk Low/High 15.56 / 21.16
Volume 173.65K
Avg Volume 191.80K
Exchange NASDAQ
Shares Outstanding 20.53M
Market Cap 415.05M
EPS 1.00
P/E Ratio 19.26
Div & Yield 0.76 (3.80%)

Latest News

Trifecta Stocks Weekly Roundup

This week we promoted International Flavors & Fragrances from the Bullpen and added it to our active portfolio, where it joined recent newbie Sherwin-Williams.

Pets Are Big Business Now and These Stocks Are Behind the Trend

Pets Are Big Business Now and These Stocks Are Behind the Trend

TheStreet's Jim Cramer says the humanization of pets is a growing investment opportunity.

Pets Are Family Now and These Stocks Are Best in Show

Pets Are Family Now and These Stocks Are Best in Show

The humanization of pets has sent spending soaring, which has some pet-related stock seeing major benefits.

Trifecta Stocks Weekly Roundup

We welcomed paint maker Sherwin-Williams into the Trifecta portfolio fold this week.

PETS Ex-Dividend Reminder - 8/4/16

PETS Ex-Dividend Reminder - 8/4/16

Looking at the universe of stocks we cover at Dividend Channel, on 8/4/16, PetMed Express Inc will trade ex-dividend, for its quarterly dividend of $0.19, payable on 8/19/16. As a percentage of PETS's recent stock price of $20.85, this dividend works out to approximately 0.91%, so look for shares of PetMed Express Inc to trade 0.91% lower — all else being equal — when PETS shares open for trading on 8/4/16.

Trifecta Stocks Weekly Roundup

Favorable results from Alphabet and PetMed Express led us to raise our price targets on those stocks.

PetMed's Chart Has Reached Animal Spirits

PETS has been a winner for the portfolio and a pullback would set up a nice buying opportunity.

Take Profits in PetMed, Then Wait for a Pullback

Take Profits in PetMed, Then Wait for a Pullback

At best, the stock should be priced at around $18, or 12% lower.

PetMed Reports a Tail-Thumping Bottom-Line Beat

We suspect Wall Street will be boosting its expectations for the back half of 2016.

Trifecta Stocks Weekly Roundup

In a week that saw the market continue to rise and several strong performers in the portfolio, we exited one position and trimmed another.

Jim Cramer's Top Takeaways: Zoetis, Idexx, Danaher, Fortive

Jim Cramer's Top Takeaways: Zoetis, Idexx, Danaher, Fortive

Cramer is faithful to pet care drug maker Zoetis and he prefers Danaher over its split-off sibling Fortive.

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.

Trifecta Stocks Weekly Roundup

Most of our portfolio names did well, though we did downgrade AT&T and Costco to Twos from Ones because of the moves higher in their shares in recent weeks.

Strong Retail-Sales Report Is Good News for Our Portfolio

UPS, Alphabet, Foot Locker and other holdings should benefit.

Trifecta Stocks Weekly Roundup

This week we booked a profit trimming one position while another holding effected a planned spinoff.

Post-Brexit, a Dog Is an Investor's Best Friend

Post-Brexit, a Dog Is an Investor's Best Friend

When the going gets tough, investors should snuggle up to the stable pet industry.

Trifecta Stocks Weekly Roundup

Ongoing uncertainty gave a boost to some of the portfolio's more defensive names, including AT&T and Randgold Resources.

PetMed Express Is Not in the Doghouse

Now may be a good time to add to positions.

Trifecta Stocks Weekly Roundup

Our inverse ETFs and Randgold Resources were solid performers this week thanks to today's Brexit-inspired market turmoil.

Brexit Is a Go, Now What?

How it affects the Trifecta Stocks portfolio, and how we are playing it today and going forward.

Trifecta Stocks Weekly Roundup

We added one new position to the portfolio in a week dominated by the upcoming Brexit vote.

Fed's Message Is Loud and Clear

The central bank is telling us that any eventual move upward in rates will be 'gradual.'

Trifecta Stocks Weekly Roundup

Our first inclination is to do no harm to the portfolio, which is why are careful in taking new positions, as we did this week in Alphabet.

Trifecta Stocks Weekly Roundup

We've got plenty of cash on hand to take advantage of any "June swoon" decline in the stock prices of quality companies.

Jobs Report Bodes Well for Several Portfolio Positions

Investors are likely to shift their focus to safer-haven, inelastic business model companies and dividend payers.

What to Make of the Manufacturing Reports?

We are likely to see current-quarter GDP forecasts reduced.